World Health Organization Sounds Alert Over Acute Lack of Obesity Injections

Fewer than one in 10 people who could benefit from weight-loss injections such as Wegovy are able to get them, warns the global health agency as it publishes its initial recommendations on the medications.

With over a billion people worldwide now living with obesity, it is advocating for more widespread and fairer access to GLP-1 medication.

Based on forecasts, in excess of 2,000,000,000 could be living with obesity by 2030 unless action is taken.

"Our latest guidance affirms that obesity is a long-term condition that can be managed with holistic and lifelong treatment," stated WHO director-general Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and distribution challenges are key barriers to universal availability to the injections that can aid individuals in losing significant body mass, explains the agency.

Skinny Jab Shortage

Even in the present most optimistic outlook, the manufacturing of such drugs could only cover around 100 million people – fewer than 10% of eligible patients, as stated by the WHO.

The guideline encourages nations and manufacturers to widen availability, by strategies such as voluntary licensing.

A patent on a key compound – the primary ingredient of a leading brand – is due to expire in multiple countries in 2026.

The Way Obesity Drugs Work

These medications mimick a biological compound to delay gastric emptying, curb appetite and boost the sense of being full so individuals eat less.

People commonly begin shedding pounds in the initial weeks of beginning the regular doses.

Studies suggests patients may put most of the weight back on after a year of discontinuing the medication, because their normal food cravings return.

Being carrying excess weight increases your chance for contracting health problems, like type 2 diabetes, heart disease, brain attack, and certain cancers.

Obesity impacts individuals in every country and was associated with over three and a half million fatalities worldwide in 2024, per the health agency.